TECHNOLOGY LICENSING OPPORTUNITY: SignalGen

Special NoticeNo Set AsideActive

Key Takeaways

  • Set-aside for No Set Aside businesses
  • Work to be performed in Columbus, OH
  • Industry: Research and Development in Biotechnology (except Nanobiotechnology)

Contract Details

Notice ID
S-195368
Opportunity Type
Special Notice
Sub-Agency
ENERGY, DEPARTMENT OF
Office
TRIAD - DOE CONTRACTOR
Posted Date
Tuesday, September 22, 2026
Response Deadline
Monday, March 22, 2027
PSC Code
AN12
Set-Aside
No Set Aside
Place of Performance
Columbus, OH, 43201
Status
Active

Description

A platform that predicts the right signal peptide for a specific protein Many medicines, vaccines, and biotechnology products rely on proteins reaching the right cellular compartment or secretion outside a cell. Whether a protein gets there in enough quantities depends on its signal peptide or leader sequence. Scientists can identify many existing signal peptides, but predicting which one will work best for a specific protein remains difficult. SignalGen uses generative AI to predict the signal peptide most likely to guide a protein to the right location. To make that prediction, it considers the protein, where it needs to go, and the organism it comes from. This approach gives researchers a new way to improve protein expression for medicines, vaccines, and biotechnology products. Overview

Why This Opportunity Matters

ENERGY, DEPARTMENT OF is seeking responses for research and development in biotechnology (except nanobiotechnology) with a set-aside for No Set Aside businesses in Columbus, OH. This set-aside designation means eligible businesses face reduced competition from larger firms.